… randomized studies is largely lacking. To address this gap, we undertook a prospective
randomized phase I/II trial in which the phase I … regimens, and the phase II component evaluated …

Background The addition of atezolizumab to carboplatin and etoposide (CP/ET) significantly
improved progression-free and overall survival for patients with extensive-stage small-cell …

… the most commonly used frontline treatment of extensive-stage small-cell lung cancer (ES-SCLC).
Although this regimen induces objective tumor response in 50% to 70% of patients, …

… Prophylactic cranial irradiation (PCI) is considered standard of care in patients with
limited-stage small-cell lung cancer (SCLC) 1,2 and is still under debate in extensive disease. The …

… II (randomized, double-blind placebo-controlled) study of the safety, efficacy and PK of … for
treatment-naive extensive-stage small-cell lung cancer patients. Patients received trilaciclib or …

… This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared
… -mutated non–small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768 ). …

Background PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line
treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there …

… non-small-cell lung cancer (NSCLC). … Randomized phase III study of surgery alone or
surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer…

… In conclusion, 5-year outcomes from the randomized phase III CheckMate 017 and 057
trials … These findings represent an important advancement in the treatment of lung cancer. …

… with EGFR mutation-positive non-small-cell lung cancer (NSCLC) in mainland China. Most
… string of “(lung cancer) AND (EGFR)” and limited the results to phase 2 and phase 3 studies …